Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Nat Med
    August 2025
  1. HONG S, Wang Q, Cheng Y, Luo Y, et al
    First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.
    Nat Med. 2025 Aug 19. doi: 10.1038/s41591-025-03883.
    >> Share

  2. PREUSSER M, Garde-Noguera J, Garcia-Mosquera JJ, Gion M, et al
    Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
    Nat Med. 2025;31:2797-2805.
    >> Share

  3. CHO BC, Lu S, Lee MA, Song Z, et al
    D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial.
    Nat Med. 2025;31:2768-2777.
    >> Share

    July 2025
  4. CAMPANELLA G, Kumar N, Nanda S, Singi S, et al
    Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.
    Nat Med. 2025 Jul 9. doi: 10.1038/s41591-025-03780.
    >> Share

  5. ZHOU C, Dong X, Chen G, Wang Z, et al
    Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
    Nat Med. 2025;31:2375-2384.
    >> Share

    June 2025
  6. MA Y, Yang Y, Huang Y, Fang W, et al
    A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
    Nat Med. 2025;31:1949-1957.
    >> Share

    May 2025
  7. CASCONE T, Bonanno L, Guisier F, Insa A, et al
    Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
    Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746.
    >> Share

  8. SKOULIDIS F, Li BT, de Langen AJ, Hong DS, et al
    Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer.
    Nat Med. 2025 May 28. doi: 10.1038/s41591-025-03732.
    >> Share

  9. ZHENG MM, Zhou Q, Chen HJ, Jiang BY, et al
    Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.
    Nat Med. 2025;31:1547-1556.
    >> Share

    April 2025
  10. ZHAO S, Cheng Y, Wang Q, Li X, et al
    Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
    Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638.
    >> Share

    March 2025
  11. HERBST RS, John T, Grohe C, Goldman JW, et al
    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
    Nat Med. 2025 Mar 17. doi: 10.1038/s41591-025-03577.
    >> Share

    February 2025
  12. TAGORE S, Caprio L, Amin AD, Bestak K, et al
    Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.
    Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03530.
    >> Share

    January 2025
  13. SHI Y, Fang J, Xing L, Yao Y, et al
    Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial.
    Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03401.
    >> Share

  14. BLACK JRM, Bartha G, Abbott CW, Boyle SM, et al
    Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.
    Nat Med. 2025;31:70-76.
    >> Share

  15. ZUCCATO JA, Mamatjan Y, Nassiri F, Ajisebutu A, et al
    Prediction of brain metastasis development with DNA methylation signatures.
    Nat Med. 2025;31:116-125.
    >> Share

    November 2024
  16. ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al
    Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
    Nat Med. 2024;30:3209-3222.
    >> Share

  17. WANG C, Shao J, He Y, Wu J, et al
    Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
    Nat Med. 2024;30:3184-3195.
    >> Share

    September 2024
  18. LI N, Wang SY
    Navigating treatment combinations in small-cell lung cancer.
    Nat Med. 2024 Sep 18. doi: 10.1038/s41591-024-03255.
    >> Share

  19. JEE J, Brannon AR, Singh R, Derkach A, et al
    DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
    Nat Med. 2024;30:2499-2507.
    >> Share

    August 2024
  20. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178.
    >> Share

    July 2024
  21. CHENG Y, Chen J, Zhang W, Xie C, et al
    Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132.
    >> Share

    June 2024
  22. PETERS S, Gadgeel SM, Mok T, Nadal E, et al
    Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008.
    >> Share

  23. WIDMAN AJ, Shah M, Frydendahl A, Halmos D, et al
    Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Nat Med. 2024;30:1655-1666.
    >> Share

    May 2024
  24. SHIELDS MD, Lovly CM
    Refining neoadjuvant immunotherapy for resectable lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-03001.
    >> Share

  25. ZENG Y, Hu CH, Li YZ, Zhou JS, et al
    Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02929.
    >> Share

    April 2024
  26. SCHULER M, Cuppens K, Plones T, Wiesweg M, et al
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965.
    >> Share

  27. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    >> Share

  28. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    >> Share

  29. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    >> Share

  30. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    >> Share

    February 2024
  31. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    >> Share

    October 2023
  32. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    >> Share

  33. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
    >> Share

  34. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
    ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
    Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
    >> Share

    September 2023
  35. CHO BC, Kim DW, Spira AI, Gomez JE, et al
    Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016